A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection

Vaccine ◽  
1994 ◽  
Vol 12 (15) ◽  
pp. 1467-1472 ◽  
Author(s):  
S. Kodihalli ◽  
V. Sivanandan ◽  
K.V. Nagaraja ◽  
D. Shaw ◽  
D.A. Halvorson
Keyword(s):  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Protective Immunity ◽  
Subunit Vaccine ◽  
Challenge Infection

scholarly journals Contributions of the Avian Influenza Virus HA, NA, and M2 Surface Proteins to the Induction of Neutralizing Antibodies and Protective Immunity

2009 ◽  
Vol 84 (5) ◽  
pp. 2408-2420 ◽  
Author(s):  
Baibaswata Nayak ◽  
Sachin Kumar ◽  
Joshua M. DiNapoli ◽  
Anandan Paldurai ◽  
Daniel R. Perez ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Neutralizing Antibodies ◽  
Protective Immunity ◽  
Reverse Genetics ◽  
Severe Disease ◽  
Serum Antibody ◽  
Surface Proteins ◽  
Serum Antibodies

ABSTRACT Highly pathogenic avian influenza virus (HPAIV) subtype H5N1 causes severe disease and mortality in poultry. Increased transmission of H5N1 HPAIV from birds to humans is a serious threat to public health. We evaluated the individual contributions of each of the three HPAIV surface proteins, namely, the hemagglutinin (HA), the neuraminidase (NA), and the M2 proteins, to the induction of HPAIV-neutralizing serum antibodies and protective immunity in chickens. Using reverse genetics, three recombinant Newcastle disease viruses (rNDVs) were engineered, each expressing the HA, NA, or M2 protein of H5N1 HPAIV. Chickens were immunized with NDVs expressing a single antigen (HA, NA, and M2), two antigens (HA+NA, HA+M2, and NA+M2), or three antigens (HA+NA+M2). Immunization with HA or NA induced high titers of HPAIV-neutralizing serum antibodies, with the response to HA being greater, thus identifying HA and NA as independent neutralization antigens. M2 did not induce a detectable neutralizing serum antibody response, and inclusion of M2 with HA or NA reduced the magnitude of the response. Immunization with HA alone or in combination with NA induced complete protection against HPAIV challenge. Immunization with NA alone or in combination with M2 did not prevent death following challenge, but extended the time period before death. Immunization with M2 alone had no effect on morbidity or mortality. Thus, there was no indication that M2 is immunogenic or protective. Furthermore, inclusion of NA in addition to HA in a vaccine preparation for chickens may not enhance the high level of protection provided by HA.

scholarly journals Protection of cats against lethal influenza H5N1 challenge infection

2008 ◽  
Vol 89 (4) ◽  
pp. 968-974 ◽  
Author(s):  
Thomas W. Vahlenkamp ◽  
Timm C. Harder ◽  
Matthias Giese ◽  
Fengsheng Lin ◽  
Jens P. Teifke ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Influenza Virus Vaccine ◽  
Challenge Infection ◽  
Wild Birds ◽  
High Dose ◽  
Human Patient ◽  
Pathogenic Avian Influenza Virus

Highly pathogenic avian influenza virus (HPAIV) H5N1 of Asian origin continues to circulate in poultry and wild birds, causing considerable concern for veterinary and public health in Asia, Europe and Africa. Natural transmission of HPAIV H5N1 from poultry to humans, resulting in infections associated with high mortality, and from poultry or wild birds to large felids and domestic cats has been reported. Experimental infection of cats with HPAIV H5N1 derived from a human patient resulted in lethal disease. The role of cats in the adaptation of HPAIV H5N1 to mammals and vaccination regimens for the eventual protection of cats, however, remain to be elucidated. Here, it was shown that cats can be protected against a lethal high-dose challenge infection by an inactivated, adjuvanted heterologous H5N6 avian influenza virus vaccine. The challenge HPAIV H5N1 was derived from a naturally infected cat. In non-vaccinated cats, low-dose exposure resulted in asymptomatic infections with minimal virus excretion. As diseased cats can transmit the infection to naïve contact animals, the epidemiological role of H5N1-infected cats in endemically infected areas as a link between wild birds, poultry and humans needs close inspection, and vaccination of cats should be considered to reduce possible human exposure.

scholarly journals Neuraminidase in Virus-Like Particles Contributes to the Protection against High Dose of Avian Influenza Virus Challenge Infection

Pathogens ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. 1291
Author(s):  
Hae-Ji Kang ◽  
Ki-Back Chu ◽  
Keon-Woong Yoon ◽  
Gi-Deok Eom ◽  
Jie Mao ◽  
...  
Keyword(s):  
Influenza Virus ◽  
T Cell ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Critical Role ◽  
Protective Role ◽  
Challenge Infection ◽  
High Dose ◽  
Post Challenge ◽  
Virus Challenge

Neuraminidase is an important target for influenza vaccination. In this study, we generated avian influenza VLPs, expressing hemagglutinin (HA), neuraminidase (NA), HA and NA co-expressed (HANA), to evaluate the protective role of NA against a high (10LD50) and low (2LD50) dose of avian influenza virus challenge infections. A single immunization with HANA VLPs elicited the highest level of virus-specific IgG, IgG1, and IgG2a responses from the sera post-vaccination and the lungs post-challenge-infection. Potent antibody-secreting cell responses were observed from the spleens and lungs of HANA-VLP-immunized mice post-challenge-infection. HANA VLPs induced the highest CD4+ T cell, CD8+ T cell, and germinal center B cells, while strongly limiting inflammatory cytokine production in the lungs compared to other VLP immunization groups. In correlation with these findings, the lowest bodyweight losses and lung virus titers were observed from HANA VLP immunization, and all of the immunized mice survived irrespective of the challenge dose. Contrastingly, VLPs expressing either HA or NA alone failed to elicit complete protection. These results indicated that NA in VLPs played a critical role in inducing protection against a high dose of the challenge infection.

scholarly journals Protection of Chickens with Maternal Avian Influenza Virus (AIV) Immunity after Vaccination with a Recombinant AIV-Newcastle Disease Vector

Proceedings ◽  
2020 ◽  
Vol 50 (1) ◽  
pp. 83
Author(s):  
Magdalena Murr ◽  
Olayinka Asala ◽  
Axel Karger ◽  
Christian Grund ◽  
Thomas C. Mettenleiter ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Newcastle Disease ◽  
Matrix Protein ◽  
Protective Efficacy ◽  
Vaccine Virus ◽  
Challenge Infection ◽  
Surface Proteins ◽  
Disease Vector

Highly pathogenic avian influenza virus (HPAIV) belongs to the Orthomyxoviridae family and causes a systemic and highly lethal disease in poultry. Vaccination with recombinant Newcastle disease vector viruses (NDV) expressing the hemagglutinin (HA) of HPAIV H5N1 induces high antibody titers in chickens free of specific pathogens, conveying protection against a lethal infection with HPAIV H5N1. Protection of chickens possessing maternally derived NDV immunity was achieved after the replacement of the surface proteins of NDV, the fusion protein (F), and the hemagglutinin-neuraminidase protein (HN) against those of avian paramyxovirus serotype 8. However, maternal AIV antibodies (αAIV-MDA+) still interfere with vaccine virus replication, resulting in inefficient protection. For our study, recombinant rNDVsolH5_H5 was generated. The insertion of a transgene encoding a truncated soluble HA between the NDV phosphoprotein and matrix protein genes—in addition to the gene encoding a membrane-bound HA inserted between the NDV, F and HN of the lentogenic NDV Clone 30 —was expected to increase the total amount of HA expressed by the recombinant virus. Western blot and mass spectrometry analyses confirmed the increase in HA expression compared to the parental rNDVH5 expressing only the full-length HA. The protective efficacy of the newly generated recombinant NDV was tested in an animal experiment. αAIV-MDA+ chickens were vaccinated either 7, 14, or 21 days after hatching. A homologous challenge infection was carried out three weeks later. Although the youngest chickens showed the highest titer of αAIV-MDA, there were no AIV antibodies detectable 21 days after vaccination. However, 40% of vaccinated chickens were protected, while 85% and 100% protection was observed in the middle-aged and oldest chickens, which had low and no detectable levels of αAIV-MDA, and moderate and high AIV antibody levels after vaccination, respectively. Challenge infection of non-vaccinated chickens resulted in high mortality.

Sign in / Sign up

Export Citation Format

Share Document